FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2139163630> ?p ?o ?g. }

• W2139163630 endingPage "625" @default.
• W2139163630 startingPage "619" @default.
• W2139163630 abstract "Objectives To determine whether oral administration of the antifungal fluconazole during the entire period of treatment of bacterial peritonitis (BP), exit-site infection (ESI), or tunnel infection (TI) prevents later appearance of fungal peritonitis (called secondary) in patients with chronic kidney disease stage 5 in a peritoneal dialysis (PD) program. Patients and Methods All patients treated in the PD program in RTS Ltda Sucursal Caldas, during the period 1 June 2004 to 30 October 2007 were screened. Patients that had infectious bacterial complications (BP, ESI, TI) were included in a prospective randomized trial to receive or not receive oral fluconazole (200 mg every 48 hours) throughout the time period required by the administration of therapeutic antibiotics via any route. It was evaluated whether the fungal peritonitis complication appeared within 30 – 150 days following the end of antibacterial treatment. Based on local results, the sample size necessary to obtain statistically significant results was determined to be 434 episodes of peritonitis. Results The 434 episodes of peritonitis presented between the previously specified dates and during this same period there were 174 ESI or TI, of which only 52 received oral antibiotic treatment. Information in relation to consumption of antibiotics for purposes other than BP, ESI, and TI was not reliable and thus this variable was excluded. Among the episodes of peritonitis, 402 (92.6%) were of bacterial origin and 32 (7.3%) were mycotic, mainly Candida species [30 (93.75%)]. Of the fungal peritonitis, 14 (43.73%) were primary (without prior use of antibiotics) and 18 (56.25%) were secondary. In the group of patients that received prophylaxis with fluconazole (210 for BP and 26 for ESI or TI), only 3 occurrences of fungal peritonitis were observed within 30 – 150 days of its administration, which is opposite to the group without prophylaxis (210 for BP and 26 for ESI or TI), in which 15 occurrences of fungal peritonitis were detected. Statistical analysis of the group of patients with BP found comparisons of the proportions of those receiving fluconazole (0.92%) or not (6.45%) presented a highly significant difference in favor of prophylaxis ( p = 0.0051, Z = 2.8021). Given that only 1 patient in each group with ESI or TI, with or without prophylaxis, presented the complication fungal peritonitis, it was concluded that this result was not statistically significant. During laparoscopic surgery attempting reintroduction of the peritoneal catheter, it was found that 11 patients had severe adhesions or peritoneal fibrosis leading to obliteration of the peritoneal cavity. In 19 patients, reintroduction of the catheter was possible and the patients returned to PD without consequence. Conclusion In patients with bacterial peritonitis, administration of prophylactic oral fluconazole throughout the time they received antibiotics significantly prevented the appearance of secondary fungal peritonitis." @default.
• W2139163630 created "2016-06-24" @default.
• W2139163630 creator A5004817154 @default.
• W2139163630 creator A5021431378 @default.
• W2139163630 creator A5024943194 @default.
• W2139163630 date "2010-11-01" @default.
• W2139163630 modified "2023-10-09" @default.
• W2139163630 title "Fungal Peritonitis in Peritoneal Dialysis Patients: Successful Prophylaxis with Fluconazole, as Demonstrated by Prospective Randomized Control Trial" @default.
• W2139163630 cites W1573189709 @default.
• W2139163630 cites W1902685497 @default.
• W2139163630 cites W1966375039 @default.
• W2139163630 cites W1978341756 @default.
• W2139163630 cites W1986955409 @default.
• W2139163630 cites W1996281296 @default.
• W2139163630 cites W2004670254 @default.
• W2139163630 cites W2020567201 @default.
• W2139163630 cites W2021274184 @default.
• W2139163630 cites W2022844872 @default.
• W2139163630 cites W2033575741 @default.
• W2139163630 cites W2042982101 @default.
• W2139163630 cites W2043823379 @default.
• W2139163630 cites W2050733782 @default.
• W2139163630 cites W2054722634 @default.
• W2139163630 cites W2059305865 @default.
• W2139163630 cites W2060616864 @default.
• W2139163630 cites W2062358255 @default.
• W2139163630 cites W2072658270 @default.
• W2139163630 cites W2107333376 @default.
• W2139163630 cites W2108486619 @default.
• W2139163630 cites W2113029574 @default.
• W2139163630 cites W2113405516 @default.
• W2139163630 cites W2122879037 @default.
• W2139163630 cites W2124012665 @default.
• W2139163630 cites W2134124451 @default.
• W2139163630 cites W2136723088 @default.
• W2139163630 cites W2138130690 @default.
• W2139163630 cites W2153828715 @default.
• W2139163630 cites W2154807147 @default.
• W2139163630 cites W2178291003 @default.
• W2139163630 cites W2188119588 @default.
• W2139163630 cites W2233028245 @default.
• W2139163630 cites W2265007812 @default.
• W2139163630 cites W2313626137 @default.
• W2139163630 cites W2328681450 @default.
• W2139163630 cites W2340173499 @default.
• W2139163630 cites W2396256037 @default.
• W2139163630 cites W2409282411 @default.
• W2139163630 cites W2411395895 @default.
• W2139163630 cites W2416904256 @default.
• W2139163630 cites W2421862445 @default.
• W2139163630 doi "https://doi.org/10.3747/pdi.2008.00189" @default.
• W2139163630 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20634438" @default.
• W2139163630 hasPublicationYear "2010" @default.
• W2139163630 type Work @default.
• W2139163630 sameAs 2139163630 @default.
• W2139163630 citedByCount "60" @default.
• W2139163630 countsByYear W21391636302012 @default.
• W2139163630 countsByYear W21391636302013 @default.
• W2139163630 countsByYear W21391636302014 @default.
• W2139163630 countsByYear W21391636302015 @default.
• W2139163630 countsByYear W21391636302016 @default.
• W2139163630 countsByYear W21391636302017 @default.
• W2139163630 countsByYear W21391636302018 @default.
• W2139163630 countsByYear W21391636302019 @default.
• W2139163630 countsByYear W21391636302020 @default.
• W2139163630 countsByYear W21391636302021 @default.
• W2139163630 countsByYear W21391636302022 @default.
• W2139163630 countsByYear W21391636302023 @default.
• W2139163630 crossrefType "journal-article" @default.
• W2139163630 hasAuthorship W2139163630A5004817154 @default.
• W2139163630 hasAuthorship W2139163630A5021431378 @default.
• W2139163630 hasAuthorship W2139163630A5024943194 @default.
• W2139163630 hasBestOaLocation W21391636301 @default.
• W2139163630 hasConcept C126322002 @default.
• W2139163630 hasConcept C141071460 @default.
• W2139163630 hasConcept C16005928 @default.
• W2139163630 hasConcept C168563851 @default.
• W2139163630 hasConcept C188816634 @default.
• W2139163630 hasConcept C2778653478 @default.
• W2139163630 hasConcept C2779056158 @default.
• W2139163630 hasConcept C2779548794 @default.
• W2139163630 hasConcept C2779978075 @default.
• W2139163630 hasConcept C2780199535 @default.
• W2139163630 hasConcept C2780651595 @default.
• W2139163630 hasConcept C501593827 @default.
• W2139163630 hasConcept C71924100 @default.
• W2139163630 hasConcept C81182388 @default.
• W2139163630 hasConcept C86803240 @default.
• W2139163630 hasConcept C89423630 @default.
• W2139163630 hasConcept C90924648 @default.
• W2139163630 hasConceptScore W2139163630C126322002 @default.
• W2139163630 hasConceptScore W2139163630C141071460 @default.
• W2139163630 hasConceptScore W2139163630C16005928 @default.
• W2139163630 hasConceptScore W2139163630C168563851 @default.
• W2139163630 hasConceptScore W2139163630C188816634 @default.
• W2139163630 hasConceptScore W2139163630C2778653478 @default.
• W2139163630 hasConceptScore W2139163630C2779056158 @default.
• W2139163630 hasConceptScore W2139163630C2779548794 @default.

• next